Nephrology & urology
Kidney & urinary clinical trials
Kidney disease and conditions of the bladder and urinary tract. We’re tracking 4,505 recruiting studies in this area right now.
By phase
- Not applicable2,822
- Phase 2562
- Phase 1366
- Phase 3271
- Phase 1/Phase 2230
- Phase 4195
- Phase 2/Phase 359
Top conditions
- Prostate Cancer651
- Bladder Cancer192
- Acute Kidney Injury136
- Chronic Kidney Diseases131
- Breast Cancer105
- Chronic Kidney Disease104
- Renal Cell Carcinoma80
- Urinary Incontinence64
- Colorectal Cancer60
- Kidney Cancer60
- Ovarian Cancer60
- Lung Cancer56
- Lupus Nephritis53
- Cancer51
- Melanoma50
- Benign Prostatic Hyperplasia48
- Head and Neck Cancer46
- Prostate Cancer (Adenocarcinoma)46
Leading sponsors
- Mayo Clinic62
- National Cancer Institute (NCI)45
- Peking University First Hospital38
- M.D. Anderson Cancer Center36
- Chinese University of Hong Kong34
- Novartis Pharmaceuticals34
- AstraZeneca29
- Memorial Sloan Kettering Cancer Center29
- Assistance Publique - Hôpitaux de Paris28
- University of California, San Francisco28
Where studies are running
- California350
- Alabama111
- Arizona103
- Florida97
- New York95
- Maryland91
- Texas91
- Massachusetts88
- Illinois66
- Ohio48
Recruiting studies4,505 total
- NCT05783271Recruiting
MRI test accuracy for suspected bladder cancer
This study checks how accurate a specific MRI measurement method is for people who may have bladder cancer. It may help doctors choose the best way to confirm or rule out cancer using MRI.
Asyut, AssuitAges Any age - NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05785052Recruiting
Study kidney cancer clues in blood or tissue markers
This study looks for “biomarkers,” which are measurable signs (often from blood or tissue), to better understand kidney cancer. It may help doctors identify who has kidney cancer and how it behaves.
FlorenceAges 18 years+ - NCT05786742Recruiting
Radiation plan test for early prostate cancer with a boost
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
QuébecAges 18–95 - NCT05786443RecruitingPhase 2
Empagliflozin test in adults on regular dialysis
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Boston, MassachusettsAges 18 years+ - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT05786768RecruitingPhase 2/Phase 3
Obinutuzumab vs rituximab for relapsing childhood kidney syndrome
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
ParisAges 3–18 - NCT05788276RecruitingPhase 4
Dapagliflozin to help transplanted kidneys stay healthy
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
Oslo, OsloAges 18–75 - NCT05790213RecruitingPhase 2
Hormone therapy plus targeted prostate treatment for intermediate cancer
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Chicago, IllinoisAges 18 years+ - NCT05790850Recruiting
Mindfulness and exercise plan before bladder surgery
This study tests whether a structured mindfulness and high-intensity exercise program before radical bladder surgery can help patients improve health and recovery. You may be asked to use monitoring devices and complete questionnaires during the study.
Charlottesville, VirginiaAges 18–90 - NCT05791162Recruiting
Looking at immune cell ratios in IgA kidney disease
This study looks at how certain immune cells in blood relate to IgA nephropathy, a kidney condition. It may help doctors understand which patients are likely to do better and guide future care.
BesançonAges 18 years+ - NCT05792722Recruiting
Testing a prostate-sparing bladder surgery for bladder cancer
This trial studies whether a “prostate-sparing” radical cystectomy is safe and effective for bladder cancer patients who are having surgery. It aims to see if this approach can treat bladder cancer while reducing prostate-related side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05795140RecruitingPhase 3
Long-term safety study of iptacopan for aHUS
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
São Paulo, São PauloAges 18–100 - NCT05796973RecruitingPhase 3
Exercise and atorvastatin for metastatic cancer outcomes
This trial tests whether a structured exercise program, along with the cholesterol medicine atorvastatin, can improve outcomes in people with metastatic prostate, breast, ovarian, or kidney cancer. It may help by reducing inflammation and supporting physical function during cancer treatment.
Tampere, Länsi-SuomiAges 18–99 - NCT05797649Recruiting
Test a pleural fluid blood marker to tell heart failure vs others
This study checks whether a substance called NT-proBNP in pleural fluid can better identify if fluid around the lung is caused by heart failure. If you fit, the results may help doctors choose faster, more accurate diagnosis for your pleural effusion.
Hong Kong, New TerritoriesAges 18 years+ - NCT05798403Recruiting
Electroacupuncture vs bladder pills for overactive bladder
This trial compares electroacupuncture (a type of acupuncture using mild electrical stimulation) with solifenacin, a bladder medication, for women with overactive bladder. It aims to see which treatment works better to reduce bladder urgency and frequent urination.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05802121RecruitingEarly Phase 1
Testing a gut bacteria supplement side effects during prostate hormone therapy
This early-phase study looks at how changing gut bacteria (especially Akkermansia) affects metabolic side effects in men starting prostate hormone therapy (ADT). It may help researchers understand how to reduce or manage side effects for people on ADT.
London, OntarioAges 18 years+ - NCT05803941RecruitingPhase 4
Study long-term safety of a prostate cancer drug
This trial checks the long-term safety (how it affects you over time) of lutetium-177 vipivotide tetraxetan in people with prostate cancer. You may be eligible if you already received the related drug in a prior Novartis prostate cancer study and can complete the required follow-up tests.
Scottsdale, ArizonaAges 18–100 - NCT05804318Recruiting
Adaptive daily radiation for low- and intermediate-risk prostate cancer
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
Duarte, CaliforniaAges 18 years+ - NCT05805202Recruiting
Study rare gene changes in atypical HUS for tailored care
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
Ranica, BGAges Any age - NCT05805436RecruitingPhase 4
Laxatives before robotic prostate or kidney surgery
This trial tests whether giving a laxative before certain robotic urologic surgeries improves bowel function after surgery. It may help reduce constipation and related discomfort during recovery.
Iowa City, IowaAges 30–100 - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT05806645Recruiting
Digital tools to guide recovery after a kidney injury
This study uses personalized risk information and digital tools to help people plan safe transitions after a recent hospital kidney injury. The goal is to better guide next steps and reduce the chance of future kidney problems.
Calgary, AlbertaAges 18 years+
Common questions
- How many kidney & urinary clinical trials are recruiting?
- Clin2 is tracking 4,505 recruiting nephrology & urology studies from the U.S. registry right now, out of 7,180 we cover in this area in total.
- What does “Kidney & urinary” cover here?
- Kidney disease and conditions of the bladder and urinary tract. We group each study into kidney & urinary based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a kidney & urinary trial near me?
- Use the search to filter kidney & urinary studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.